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Edmonton Obesity Staging System for Pediatrics, Quality of Life, Fitness, Adherence to Exercise in 
Adolescents with Obesity 
Gabriel A. Kakon 
Background: The Edmonton Obesity Staging System-pediatrics (EOSS-p) is based on the EOSS for 
adults, which has shown better predictive value for mortality than BMI. To our knowledge, no study 
has examined the EOSS-p in relation to health and wellbeing outcomes in a pediatric sample with 
obesity. The purpose of this study was to compare the associations of EOSS-p and BMI percentile with 
quality of life (QOL), cardiorespiratory fitness (CRF), muscular strength, and adherence to an exercise 
intervention in adolescents with obesity.  
Methods: Participants were enrolled in the Healthy Eating Aerobics Resistance Training in Youth trial 
(N= 299). QOL, CRF (peak oxygen uptake, VO2peak) and muscular strength were assessed by the 
Pediatric QOL Inventory (PedsQL), indirect calorimetry during a maximal treadmill test, and 8-RM 
bench and leg press tests respectively. QOL, CRF, and muscular strength were assessed at baseline and 
6-months after the intervention. Adherence was determined as a percentage of attended exercise 
sessions. Participants were staged from 0 to 3 (absent to severe health risk) according to EOSS-p. The 
association of EOSS-p and BMI percentile with outcomes were assessed using general linear models 
adjusting for age and sex.  
Results: Baseline QOL decreased with increasing EOSS-p stages (p<0.001). QOL was 75.7  11.4 in 
stage 0/1, 69.1  13.1 in stage 2, and 55.4  13.0 in stage 3. Stage 3 showed smaller improvements with 
6-month CRF than stage 0/1 and 2 (p=0.001, B=-3.882 mlO2/kg/min). BMI percentile was associated 
with baseline VO2peak (p<0.001, B=-1.044 mlO2/kg/min), bench press (p=0.029, B=0.832 kg) and leg 
press (p=0.003, B=3.992 kg). Similar associations were observed between BMI percentile and 6-month 
outcomes.  
Conclusion: As EOSS-p stages increase, QOL decreases.  EOSS-p stage 3 had lower 6-month CRF, 
which suggests stage 3 may require a longer, more intensive or different intervention to achieve similar 
CRF improvements. BMI percentile showed contradicting health associations with cardiorespiratory 
fitness and muscular strength.   
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CHAPTER 1: Introduction  
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1.0 General introduction 
 
Obesity has been considered a chronic disease due to the potential weight-related comorbidities 
associated with obesity (1). Weight-related comorbidities occur when excess adiposity negatively affects 
an individual’s metabolic, mental, and biomechanical health and wellbeing. Examples of weight-related 
comorbidities include but are not limited to cardiovascular disease, type 2 diabetes, anxiety, and 
obstructive sleep apnea (2) which can ultimately lead to decreased fitness and quality of life (QOL) (3). 
Adolescents with obesity tend to have obesity in adulthood (4), and if left untreated or uncontrolled with 
a healthy lifestyle, weight-related comorbidities can progressively worsen leading to premature mortality 
(5, 6). Exercise interventions are commonly used to manage adolescent obesity and improve health and 
wellbeing (7-9), however, adherence is essential for the effectiveness of an intervention (10, 11). 
Adherence is defined as the percentage of attended session from a prescribed intervention. In adolescents 
with obesity adherence to exercise interventions has ranged between 56% to greater than 99% (8, 12-14).   
Thus, early assessment tools that can help detect overall health, wellbeing, and adherence to an exercise 
intervention are necessary tools for managing adolescents living with obesity (15-17).    
Body mass index (BMI) is currently the most commonly used assessment tool to diagnose obesity 
in adolescents. BMI is calculated by dividing weight by height squared (kg/m2). In pediatrics, a child or 
adolescent aged 2 to 19 with a BMI ≥85th percentile for their age and sex would be considered to have 
overweight, while ≥95th percentile they would be classified as having obesity. Although BMI is practical 
and inexpensive, in recent years, it has been heavily criticized due to its overly simplistic approach to 
determining severity and biopsychosocial impacts of obesity (18, 19), its limitations in pediatric 
populations (20), and its potential to misdiagnose overweight or obesity (21-24). Two adolescents with 
the same BMI can have very different body compositions and health status. In fact, some adolescents 
with elevated BMI may be metabolically healthy (25, 26). The obesity classification by BMI does not 
provide information on how adiposity may negatively impair health and wellbeing of an adolescent. The 
World Health Organization defines health, as “a state of complete physical, mental and social well-being 
and not merely the absence of disease or infirmity” (27). Having access to a staging system of obesity 
that allows healthcare professionals to better determine the health and wellbeing of adolescents with 
obesity is necessary for guiding clinical care.    
Created in 2016, the Edmonton Obesity Staging System for pediatrics (EOSS-p) is the first 
assessment tool created to classify pediatric obesity by weight-related comorbidities and weight-
management barriers. The EOSS-p takes into account patient’s metabolic health, mental health, 
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biomechanical health, and social milieu to understand the severity of obesity prognosis and help guide 
future clinical care. EOSS-p was not intended to replace BMI percentiles, but rather to complement it by 
improving risk stratification of pediatric obesity. The EOSS-p is based on the already existing EOSS for 
adults, and is carefully tailored for usage in pediatrics (18). EOSS for adults was developed and proposed 
in 2009 by a team of Canadian medical doctors and researchers specialising in obesity (19) and was the 
first tool to classify adulthood obesity by weight-related comorbidities and weight-management barriers. 
Analogous to the staging of cancer, the EOSS staging system is based on a 5-point scale, ranging from 
stage 0 (no risk), stage 1 (mild risk), stage 2 (moderate risk), stage 3 (severe risk), to stage 4 (end stage). 
Unlike the adult version of EOSS with a 5-point staging system, the EOSS-p defines weight-related 
health-risk on a 4-point staging with four categories. The EOSS-p stages range from stage 0 (no risk), to 
stage 3 (severe risk). The EOSS-p stages are assigned for each of the following categories: metabolic 
health, mechanical health, mental health, and social milieu (4M’s). These categories represent and 
encompass weight-related comorbidities and weight-management barriers in children and adolescents 
with obesity. The adult EOSS version does not include the category social milieu, however, in children 
and adolescents, family functioning, and relationship with peers and plays an important role as enablers 
in pediatric weight-related health risk (28). Since EOSS-p was proposed in 2016, no research has been 
published on the EOSS-p. Our current understanding of EOSS-p stems from studies investigating EOSS 
for adults. Since the proposal of EOSS for adults, three studies have begun demonstrating its predictive 
validity and potential clinical utility.  
EOSS study #1: Kuk et al (2011) conducted an analysis on data from the Aerobics Center 
Longitudinal Study to assess if EOSS can identify individuals at greater mortality risk. They used a 
community cohort from Dallas, Texas of 99% white/well educated, and mid to high socioeconomic 
status. The analysis was conducted on 5483 men and 771 women (n = 6254) living with obesity, a control 
of individuals (n = 23309) with normal weight. Individuals with obesity were stratified into EOSS stages 
0 to 3, since not enough information was provided for stage 4. The researchers found that when 
comparing all-cause mortality of individuals with normal weight control to those with obesity, hazard 
ratio (HR) for stage 2 was 1.6 (95% CI 1.3-2.0), and for stage 3 was 1.7 (95% CI 1.4-2.0). When 
comparing mortality caused by cardiovascular disease, the HR for stage 2 was 2.1 (95% CI 1.6-2.8), and 
for stage 3 was 2.1 (95% CI 1.6-2.8). Here, the HR indicates the rate that mortality would occur compared 
to the control group. Stage 0 and stage 1 were not associated with elevated mortality risk, while stages 2 
and 3 had significant elevated risks of mortality, especially from cardiovascular disease. Other clinical 
variables were associated with elevated EOSS stage, including: low cardiorespiratory fitness, weight and 
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health history, weight at age 21, preferred weight, and dietary intake of fruits and vegetables. Lower 
cardiorespiratory fitness, weight, health history, weight at 21 associated with increased risk within EOSS 
stages 2 and 3. The findings suggested that EOSS is a useful tool at predicting mortality, and potentially 
to identify patients in need of weight-management interventions. Furthermore, EOSS stage 0/1 showed 
no increased risk of mortality, demonstrating that weight loss interventions may not be necessary for all 
individuals across the obesity spectrum. A limitation of this study was that the majority of participants 
were Caucasian males (>99%), therefore the results cannot be generalizable to the entire population. 
Despite these rich findings, more research is needed to determine if this system can be generalized in a 
pediatric population and in females, as well as if it can predict other important outcomes of health and 
wellbeing, and adherence to an exercise intervention.   
EOSS study #2: Padwal et al. (2011) assessed the ability of EOSS for predicting mortality 
compared to BMI from the largest US population representative cohort, the National Health and Human 
Nutrition Examination Surveys (NHANES) 1988-1994 and 1999-2004. Padwal et al.’s study included 
participants from NHANES III from 1988-1994 (n=4367) and NHANES 1999-2004 (n=3600). 
Participants were stratified into BMI categories and EOSS categories. The BMI categories were 
overweight, class 1 obesity, class 2 obesity, and class 3 obesity. EOSS categories were stage 0, 1, 2, and 
3 obesity. They were unable to assign EOSS stage 4, because NHANES did not have end-stage 
participants to assign stage 4. They found that 75% of the participants from the population-based sample 
had scores of 1 or 2. They found EOSS was a stronger predictor of mortality than BMI in the control 
group with healthy weight and in the sample with obesity (independent of BMI, metabolic syndrome 
and/or hypertriglyceridemia waist). Data from NHANES III 1988-1994 showed that after adjusting for 
BMI and metabolic syndrome, the survival rates were for EOSS stage 2 HR 1.57 (95% CI 1.16 to 2.13) 
and 3 HR 2.69 (95% CI 1.98-3.67) using EOSS stages 0/1 as reference; and for BMI class 1 obesity had 
HR 1.22 (95% CI 1.01-1.48), class 2 obesity had HR 1.73 (95% CI 1.23-2.46), and class 3 obesity had 
HR 1.52 (95% CI 0.94-2.46). After adjusting for BMI and presence of hypertriglyceridemic waist 
(combination of a waist circumference >90 cm in men or >85 cm in women, and elevated plasma 
triglyceride concentrations), EOSS stages and BMI showed consistent trends. Survival curves were used 
to graphically illustrate the predictive ability of EOSS stages versus BMI classifications for survival rate. 
According to the survival curves, the EOSS obesity stages were visibly better predictors of mortality than 
BMI obesity classifications, and are able to predict mortality rate within BMI obesity classification 
(overweight, class 1, class 2, and class 3). These findings suggest the potential clinical utility in 
prioritizing patients for bariatric surgery (29). A limitation of this study was the lack of mental health 
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assessments. Therefore, more research needs to be conducted to include EOSS mental health 
assessments, and to determine if EOSS can be used in a pediatric population. Lastly, the authors 
suggested that other outcomes such as QOL are worth investigating (6).   
EOSS study #3: Canning et al. (2015) sought to compare the effects of EOSS stage on weight 
loss of patients with obesity (n=5787) attending a referral-based weight-management clinic. They found 
a frequency distribution of 1.7% for stage 0, 10.4% for stage 1, 84% for stage 2, and 3.9% for stage 3. 
There were no EOSS stage 4 patients being treated at this weight-management clinic. The most common 
weight-related comorbidities were prehypertension, hypertension, and knee replacement surgery. They 
found that lower EOSS stages were associated with shorter treatment times. The treatment times (± SD) 
were 10.4 months (±11.7) for Stage 0, 9.4 months (± 11.5) for EOSS stage 1, 12.7 months (± 15.0) for 
EOSS stage 2, and 14.7 months (± 16.0) for EOSS stage 3. There was no significant difference between 
treatment times for stage 0 and stage 1, but there were significant differences between stage 1, 2 and 3. 
When adjusting for treatment time, lower EOSS stage was associated with greater weight loss in absolute 
kg (p<0.01) and in percentage of body weight (p<0.01). The authors suggest that weight loss programs 
should be tailored to EOSS staging, more specifically for EOSS stage 2, and 3. A limitation in this study 
was the disproportionate distribution of EOSS stages. EOSS stage 0 and 1 should be suggested weight-
gain prevention program instead. Another limitation of the study is that each participant underwent a 
different medical assessment by their physicians, meaning that not all participants had the same 
assessments done when staging with EOSS. Future research evaluating EOSS should use a sample with 
more participants in lower stages, use participants who have undergone a standardized set of assessments, 
and should investigate adherence and attrition factors.  
The three studies by Kuk et al. (2012), Padwal et al. (2012), and Canning et al (2015) shared 
some similar patterns in their findings. All four studies have found that EOSS stage 0/1 show a no risk 
to low health-related risk. Kuk et al. (2012) showed no difference in predicting all-cause mortality 
between EOSS stage 0/1 and normal weight individuals; Padwal et al. (2012) showed little to no 
differences between stage 0 and stage 1 for predicting mortality; and Canning et al. (2015) found no 
significant differences between treatment times of stage 0 and 1. Obesity in adults is traditionally defined 
by BMI 30 kg/m2, which has been identified as a risk-factor for poor health. However, based on the 
findings of these EOSS studies, people with similar BMI seem to have a very different health risk status 
according to EOSS. These promising studies have created awareness in the international bariatric 
community, and the EOSS for adults is starting to be used as an assessment tool in bariatric surgery 
research in Canada, Germany and Brazil (30). However, for the EOSS-p to create similar awareness, it 
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too must be studied. The only outcomes studied regarding EOSS to date are mortality, and weight-loss. 
To date, no study has evaluated how EOSS-p is associated with health and wellbeing, and adherence to 
exercise in children or adolescents with obesity. In order for the EOSS-p to help guide clinical treatment, 
it must be studied in a pediatric sample with obesity. 
 
 
1.1 QOL, cardiorespiratory fitness, and muscular strength 
 
Previous studies evaluating the EOSS for adults used mortality risk as an adverse health 
outcome. While mortality risk is difficult to predict in children, QOL, cardiorespiratory fitness, and 
muscular strength are feasible measures known to be good representations of health and wellbeing in 
adolescents (31, 32). QOL is consistently lower in populations with chronic disease (33), and 
promotion of QOL has been identified as an over-arching public health goal from Healthy People 2000, 
2010, and 2020 (34). Cardiorespiratory fitness is the capacity of an individual to deliver oxygen to 
working muscles and carry out long, strenuous exercise (35). Cardiorespiratory fitness has been 
proposed by the American Heart Association for routine assessment in clinical practice because of its 
strong association with cardiovascular disease and all-cause mortality (36). Higher levels of 
cardiorespiratory fitness and physical activity has been shown to significantly reduce the risk of 
mortality in individuals with obesity (5). Muscular strength, which is a component of muscular fitness, 
refers to “the ability to carry out maximal force” against a resistance (37). Cardiorespiratory and 
muscular fitness are consistently lower in populations with chronic diseases and are independently 
associated with metabolic risk factors in adolescents (31, 38). Muscular strength is associated with 
higher insulin sensitivity in adolescents (39), and is a strong predictor of mortality and life expectancy 
in adults (40). A single assessment tool that is associated with QOL, cardiorespiratory fitness, and 
muscular strength in a population of adolescents with obesity would be optimal for healthcare 




The most common obesity treatments for weight management are lifestyle behavioural programs, 
such as exercise interventions. Exercise interventions in adolescents with obesity have demonstrated 
significant physiological, biomechanical, and mental health benefits (7, 11, 41-45), including 
improvements in cardiorespiratory fitness and QOL (7, 44). A major obstacle facing the effectiveness of 
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exercise interventions is low adherence and attrition to the intervention (46, 47). Adherence can be 
defined as the extent to which a person’s behaviour corresponds to agreed intervention (48). For this 
thesis project, adherence to an exercise intervention is defined as a percentage of sessions attended out 
of the total prescribed sessions. Identifying predictors of adherence to exercise interventions would 
inform ways to address these predictors and ultimately improve adherence to exercise interventions in 
the long term.   
The body of literature assessing adherence factors in pediatric obesity weight management 
interventions is scarce, however it has been investigated in adults (46). A systematic review focusing on 
adulthood obesity, found lower baseline BMI, lower depression, stress, and anxiety to be predictors of 
adherence (46). While this systematic review identifies many potential predictors of adherence in adults 
with obesity, the number of contributing factors identified can be complex to interpret for evaluators, as 
it requires identifying each variable individually. It would be beneficial to investigate if a 
multidisciplinary pediatric obesity assessment tool like EOSS-p could predict adherence to an exercise 









The primary purpose of this thesis is to investigate EOSS-p and BMI percentile regarding their 
associations with QOL, cardiorespiratory fitness, and muscular strength. QOL, cardiorespiratory 
fitness, and muscular strength were assessed at baseline and at 6-month time points. The secondary 
objective is to determine how EOSS-p and BMI percentile are associated to adherence to an exercise 
intervention in a community sample of adolescents with overweight and obesity who participated in the 
Healthy Eating and Aerobics Resistance Training in Youth (HEARTY) randomized controlled trial (see 




1) Baseline EOSS-p stages will be negatively associated with baseline and 6 months QOL, 
cardiorespiratory fitness, and muscular strength. 
2) Baseline BMI percentile will be negatively associated with baseline and 6 months QOL, 
cardiorespiratory fitness, and muscular strength. 
3) Baseline EOSS-p stages will be negatively associated with adherence to exercise at 6 months. 
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1.5 Structure of thesis 
 
To achieve the objectives, this thesis is structured in the following manner to: 
1) Outline the overall HEARTY trial, design and methods, with specific methodology used for this 
thesis project (Methods); 
2) Identify and discuss baseline associations of EOSS-p and BMI percentile with baseline QOL, 
cardiorespiratory and muscular fitness (Manuscript 1); 
3) Identify associations of EOSS-p in comparison to BMI percentile with 6-month QOL, 
cardiorespiratory fitness, muscular fitness, and adherence to the HEARTY exercise intervention 
(Additional results); 
4) Discuss the additional results reporting associations of EOSS-p in comparison to BMI percentile 
with 6-month outcomes and adherence to the HEARTY exercise intervention (Discussion) and; 
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2.0 General Methods 
 
2.1 General research plan / HEARTY overview 
 
This thesis project is a secondary data analysis from the Healthy Eating, Aerobic and Resistance 
Training in Youth (HEARTY) randomized controlled trial completed between 2005 and 2011 (49) where 
primary outcomes have been previously reported (50). At baseline, participants completed a series of 
metabolic, mechanical, mental health, and social milieu assessments over four visits (see Figure 2 and 
Table 1). Baseline assessments included a medical history (see section 2.3), physical exam (see section 
2.4), laboratory blood tests (see section 2.5, and 2.6), mental health questionnaires (see section 2.6), QOL 
questionnaire (see section 2.7), cardiorespiratory fitness (see section 2.9), and muscular fitness (see 
section 2.10) assessments. After baseline assessments, participants entered a 4-week run-in period with 
combined aerobic and resistance exercise sessions four times per week (see section 2.11.1). Participants 
who adhered to at least 13 of the 16 prescribed exercise sessions were then randomly assigned into three 
different exercise interventions (aerobic, resistance or combined aerobic + resistance) or a non-exercise 
control group (see section 2.11.2 and 2.11.3). QOL, cardiorespiratory fitness, and muscular fitness were 




The participants (N=304) included in HEARTY were inactive post-pubertal adolescents (Tanner 
stage 4-5) with obesity aged 14-18 years old. Five participants were lacking mental health data so the 
final analysis included N=299. Participants were included in the study if their BMI was ≥95th percentile 
for their age and sex or ≥85th percentile (https://www.cdc.gov/growthcharts/) with an additional risk 
factor for diabetes or cardiovascular disease. Twenty-two (7%) participants had overweight, while n=282 
(93%) had obesity. Our sample had a mean BMI percentile of 97.8, ranging from 87.2 to 99.8. The 
exclusion criteria were:  
1) BMI larger than 45kg/m2, pregnancy, performance enhancing medications, medical conditions, 
use of medication or herbal supplement likely to affect body composition, lipids or glucose 
metabolism (metformin use was permitted if participants were on metformin prior to enrollment); 
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2) Significant weight change (increase or decrease of ≥5% during the two months before enrolment); 
uncontrolled hypertension (blood pressure >150 mmhg systolic or >95 mmhg diastolic in sitting 
position);  
3) Activity restriction due to disease, such as unstable cardiac or pulmonary disease, or significant 
arthritis;  
4) Other illnesses such as eating disorders or depression;  
5) Inability to communicate in English or French; 
6) Unwillingness, inability, or unavailable to exercise; 
7) Unwilling of subject or parent/guardian to sign the informed consent. 
Recruitment was done via advertisements on city busses, referrals from the obesity clinic at the 
Children’s Hospital of Eastern Ontario and physicians in the community, word of mouth, poster print 
advertisements, radio campaigns and in schools.  Informed consent was obtained by participants and by 
a parent or legal guardian for participants under 16. The Research Ethics Boards at the Children’s 
Hospital of Eastern Ontario and the Ottawa Hospital approved this study. 
 
2.3 Medical history 
 
The research coordinator asked HEARTY participants a series of questions to assess their medical 
history. The medical history questions included demographic information regarding age, race, 
description of family unit, parental depression, parent employment status and education level, subject 
employment status, subject academic status and academic performance. Open-ended questions were 
asked regarding previous injuries/surgeries, history of smoking, history of alcohol 
consumption/recreational drug use, medication use, and self-reported depression or other psychological 
disorders such as ADHD. If the participant was female, she was asked if she has had irregular menses. 
Parents were asked to leave the room during medical history examination while discussing drug, alcohol, 
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2.4 Physical exam 
 
A research coordinator conducted a physical examination as part of the medical history. BMI (see 
section 2.4.1), blood pressure (see section 2.4.2), and acanthosis nigricans (see section 2.4.3) and tanner 




The research coordinator measured height and weight to calculate BMI. Participants were 
instructed to remove shoes, jacket, and anything that could add weight (e.g. Keys, wallet, phone, etc.). 
Height was measured in meters (m), and weight was measured in kilograms (kg) using the Health-O-
Meter manual scale (Health O Meter, Continental Scale Corp., Bridgeview, ILL). Percentile ranks were 
attributed using CDC age- and sex-specific growth charts (≥95 percentile is obesity and ≥85 percentile 
is overweight). CDC growth charts are developed by the National Center for Health Statistics in 
collaboration with the National Center for Chronic Disease Prevention and Health Promotion in 2000 
(54). 
 
2.4.2 Blood pressure 
 
The participant was seated in a chair with back support for four minutes at rest. Blood pressure 
was then taken three consecutive times with one-minute breaks in between. The mean of the final two 
measurements was used as the final blood pressure value. 
 
2.4.3 Acanthosis nigricans 
 
A research coordinator evaluated acanthosis nigricans using the Burke Scale. The Burke Scale 
requires an observer to visually evaluate potentially affected areas, such as neck, axilla, knuckles, elbows, 
and knees. Neck severity, neck texture, and axilla are ranked on a 4-point scale. Knuckles, elbows and 
knees are reported as present or absent. The Burke Scale for assessing acanthosis nigricans has been 
validated in participants with type 2 diabetes (55).  
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2.5 Oral Glucose Tolerance Test 
 
An oral glucose tolerance test (OGTT) was completed at the Ottawa Hospital, Riverside Campus. 
The OGTT test indicates the ability for the participants’ body to metabolize blood glucose (blood sugars). 
This test compares glucose levels in the blood pre- and post- ingestion of a sugary drink.  
 For the OGTT, participants were instructed to follow an unrestricted diet consuming a minimum 
of 150g of carbohydrates daily, and perform usual physical activity for 3 days prior to testing. They were 
then instructed to fast overnight for 12 hours, drink a lot of water during the fast, and abstain from any 
strenuous physical activity for 24 hours prior to the appointment. If applicable, participants were told to 
continue any long-term drug treatments on day of testing (medications affecting glucose tolerance were 
noted).   
Participants received the OGTT the morning. Trained staff collected venous blood samples from 
participants upon their arrival at the clinic. Participants were given a 75-gram 250-300 ml glucose 
solution to drink within 10 minutes. The glucose solution was kept at room temperature between 20-
25oc. Another venous blood sample was collected two hours after glucose ingestion. Participants were 
permitted to drink water during the test, however, smoking and exercise were not permitted. Insulin 
resistance was estimated from fasting plasma glucose and insulin concentration values using the 
Homeostatic Model Assessment (56).  
 
2.6 Other laboratory blood tests 
 
A research coordinator collected blood samples from participants to perform various blood tests. 
Participants fasted for 12 hours, and refrained from physical activity for 48 hours prior to blood draws. 
The blood tests included: Hemoglobin A1c (hba1c) was evaluated using tubidimetric immunoinhibition; 
total cholesterol, HDL-C, and triglyceride levels measured using a Beckman-Coulter LX20 analyzer 
(Beckman Instruments, Brea, California, USA); low-density lipoproteins cholesterol (LDL-C) levels 
calculated using the Friedewald equation (57); blood analysis for liver enzymes aspartate transaminase 
(AST) and alanine transaminase (ALT); and testosterone levels. The Ottawa hospital 
biochemistry/hematology department conducted these blood tests. 
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2.7 Mental health questionnaires 
 
The Child Depression Inventory (CDI) (58) is a questionnaire intended to measure symptoms of 
depression in school aged children and adolescents. CDI measures five sub-factors including negative 
mood, ineffectiveness, negative self-esteem, interpersonal problems, and anhedonia. CDI is a 27-item 
questionnaire, which asks participants to pick one sentence out of three that best describes them in the 
past two weeks. Each item is scored from 0 to 3 (0=symptoms absent, 1=mild, 2=definite), with a total 
score of 52.  
To assess body image, a validated questionnaire called the Multiple Body Self-Relations 
Questionnaire – Appearance Scales (MBSRQ-AS) was used (59). The appearance evaluation (AE) 
subscale of the MBSRQ was used (7-item) for this study. The items are on a 5-point Likert scale from 
“definitely disagree” to “definitely agree”.  AE is the degree of satisfaction with their overall appearance 
(60). The AE has a .88 Cronbach’s alpha with a .81 1-month test-retest for males, and a .88 Cronbach’s 
alpha and a .91 1-month test-retest for females (60). 
The Dutch Eating Behaviour Questionnaire (DEBQ) was used to assess eating behaviour. The 
emotional eating subscale (13-items) was used for this study. The items are on a 5-point Likert scale 
from “never” to “very often”.   
 
2.8 QOL questionnaire 
 
HEARTY participants completed the 23-item Pediatrics QOL Inventory 4.0 (PedsQL) (32). The 
PedsQL is divided into four categories including: physical functioning (eight items), emotional 
functioning (five items), social functioning (five items) and school functioning (five items). Each item is 
ranked using a 5-point Likert scale ranging from “Never” to “Almost Always”. The PedsQL is a reliable 
and feasible questionnaire that has been validated to assess QOL in a sample of adolescents with obesity 
(3, 61).  This study showed that PedsQL had an internal consistency alpha of 0.80 (61). PedsQL was 
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2.9 Cardiorespiratory fitness 
 
A certified exercise physiologist assessed peak oxygen uptake (VO2peak) with indirect calorimetry 
(MOXUS Modular Metabolic System, AEI Technologies Naperville, IL, USA) during a maximal 
treadmill test, the gold standard for measurement of cardiorespiratory fitness (62). During the VO2peak 
test participants were instructed to walk on a treadmill at a progressively increasing incline following the 
modified Balke and Ware incremental treadmill protocol (63) until the participant was too tired to 
continue. Treadmill time (i.e. The duration of the cardiorespiratory fitness test from start to finish) was 
also measured. Cardiorespiratory fitness was assessed at baseline and 6-months. 
 
2.10 Muscular strength 
 
An exercise specialist assessed upper body (bench press) and lower body (leg press) muscular 
strength using 8-repetition maximum (8RM) tests. Muscular strength was assessed at baseline and 6-
month. 
 
2.11 Study protocol 
 
2.11.1 Run-in phase (weeks 1-4) 
 
After baseline assessments, participants entered a 4-week run-in period to qualify for 
randomization. The run-in program was a low intensity aerobic and resistance exercise program for four 
sessions per week. A personal trainer supervised then twice a week during, while the other two sessions 
were unsupervised. The requirement to qualify for randomization into intervention or control groups was 
a minimum of 80% adherence (13 out of 16 sessions). Once completed, the participants were randomized. 
 
2.11.2 Randomization  
 
The participants (N=304) were randomized into one of four groups: diet & aerobic (n=75), diet 
& resistance (n=78), diet & combined aerobic and resistance (n=75), or diet-only control group (n=76). 
Participants were stratified into groups by their degree of overweight (ie. 95th percentile or 95th 
percentile) and sex in random blocks of 4 to 8 participants. A statistician performed randomization via 
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the randomization program IVRS,vbvoice v5.3, Pronexus. The research coordinator remained blinded 
throughout the randomization process.  
 
2.11.3 Intervention phase (weeks 5-26) 
 
2.11.3.1 Diet  
 
Participants assigned to all four groups received a diet plan. During run-in, participants attended 
a small group education seminar on the topics of barriers in achieving healthful eating and solutions to 
overcome them, taste panels of fruits and vegetables, label reading, healthful snacks, and healthier eating 
at fast food outlets. At baseline, 3- and 6-months a dietitian hosted visits for all individuals involved in 
preparing the meals for the participants to discuss weight history, diet history, current eating habits and 
fast food consumption. Participants received additional support by phone at 6 weeks and 4 months.  
The dietitian and the participants collaborated on establishing dietary goals. Participants were 
recommended to reduce their energy consumption by 250kcal/day and balance their energy sources with 
15–20% protein, 50– 55% carbohydrates and 30% fat, as per (64).  
 
2.11.3.1 Exercise protocol 
 
After run-in, participants were allocated into exercise groups or control group. All exercise groups 
shared similarities in their protocol. Exercise interventions happened across gyms in the Ottawa and 
Gatineau regions. A binder with prescribed exercises were given to each participant. Participants were 
required to attend 4 sessions per week, with a certified personal trainer. The personal trainers would 
ensure proper technique, introduce modifications to exercises if necessary, and would ensure safe 
progressions of exercises. An exercise specialist would meet with participants every second week during 
the exercise intervention. The exercise specialist monitored adherence by reviewing sign-in sheets, 
electronic sign-in software at host gym, and exercise logs. Details of the exercise protocols can be found 
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2.12 Edmonton Obesity Staging System for pediatrics (EOSS-p)  
 
EOSS-p categorizes obesity using a 4-point staging system ranging from stage 0 (no risk), stage 
1 (mild risk), stage 2 (moderate risk), and stage 3 (severe risk). The EOSS-p stages 0-3 are assigned for 
each of the following categories: Metabolic, Mechanical, Mental health, and Social Milieu (4M’s). First, 
I assigned an EOSS-p stage to each participant for each of the 4M’s.  Second, I assigned each participant 
an overall EOSS-p stage. The overall EOSS-p stage was determined as the highest EOSS-p stage from 
the 4m’s. For example, if a participant had a metabolic stage 1, mechanical stage 1, mental health stage 
2, and social milieu stage 1, then their overall EOSS-p would have been stage 2 (moderate risk).  
Using EOSS-p guidelines from the original EOSS-p tool development (18), I consulted a team 
consisting of five experts (two clinical pediatric psychologists, one pediatric endocrinologist, and two 
obesity researchers) in May 2018 to create the EOSS-p algorithm applicable for assessment of HEARTY 
participants (see Table 2). S.H. and A.B. were two of the original creators of the published EOSS-p (18) 
and they have both contributed substantially to my Manuscript 1 as co-authors. During each consultation, 
each variable was discussed at length until a consensus was reached. In the event that there was 
disagreement between two experts, I would discuss it with the other members of the expert team to make 
a final decision. Individual one-hour weekly meetings were held with my supervisor to discuss the 
HEARTY EOSS-p algorithm prior to consulting with other experts. In addition, four 1-2 hour team 
consultation meetings by teleconference and in-person in Ottawa (including two EOSS-p experts) were 
held over a period of 1.5 months to get a final consensus for the HEARTY EOSS-p algorithm. I staged 
all participants, and a second evaluator (M.L.) evaluated a random sample (n=30, 10% of total sample) 
for interrater reliability, indicating near-perfect agreement. The interrater Cronbach’s alpha was 0.959. 
 
2.13 Statistical analysis 
 
Descriptive statistics were conducted to describe baseline characteristics of the HEARTY sample. 
Baseline characteristics were compared between EOSS-p stages using ANOVA.  I created general linear 
models to determine associations of EOSS-p and BMI percentile with QOL, cardiorespiratory fitness, 
and muscular strength. For baseline outcomes, I adjusted for age, and sex in my analysis. For 6-month 
outcomes, I adjusted for age, sex, group assignment, and the baseline assessment of outcome variable in 
question. Confounding variables (age, sex, group assignment, and baseline assessment of outcome 
variable) were determined a priori. Bonferroni’s post hoc test was used to assess differences between 
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EOSS-p stages. All analyses were conducted using statistics software IBM SPSS Statistics for Windows, 
version 24 (IBM Corp., Armonk, N.Y., USA). 
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CHAPTER 3: Results  
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Background: The Edmonton Obesity Staging System-Pediatrics (EOSS-P) is a clinical staging system 
that uses weight-related comorbidities to determine health risk in pediatric populations. The purpose of 
this study was to investigate the associations of EOSS-P and BMI percentile with quality of life (QOL), 
cardiorespiratory fitness (CRF) and muscular strength in adolescents with obesity.  
Methods: Participants were enrolled at baseline in the Healthy Eating, Aerobic and Resistance 
Training in Youth trial (BMI=34.6  4.5 kg/m2, N=299). QOL, CRF (peak oxygen uptake, VO2peak) and 
muscular strength were assessed by the Pediatric QOL Inventory (PedsQL), indirect calorimetry during 
a maximal treadmill test, and an 8-RM bench and leg press tests respectively. Participants were staged 
from 0 to 3 (absent to severe health risk) according to EOSS-P. Associations assessed using age- and 
sex-adjusted general linear models.  
Results: QOL decreased with increasing EOSS-p stages (p<0.001). QOL was 75.7  11.4 in stage 0/1, 
69.1  13.1 in stage 2, and 55.4  13.0 in stage 3. BMI percentile was associated with VO2peak  
(B= –0.044 mlO2/kg/min, p<0.001), bench press (B=0.832 kg, p=0.029) and leg press (B=3.992 kg, 
p=0.003). 
Conclusion: As EOSS-p stages increase, QOL decreases. BMI percentile showed opposite health 
associations with CRF and muscular strength. 
 
  





Obesity has been considered a chronic disease due to the potential comorbidities (1). Weight-
related comorbidities occur when excess adiposity negatively affects an individual’s metabolic, mental, 
and/or biomechanical health and wellbeing. Examples of comorbidities include but are not limited to 
cardiovascular disease, type 2 diabetes, obstructive sleep apnea, anxiety and depression (2) which can 
ultimately lead to decreased fitness and quality of life (QOL) (3). Adolescents with obesity tend to have 
obesity in adulthood (4), and if left unmanaged, weight-related comorbidities can progressively worsen 
leading to premature mortality (5, 6). Thus, early assessment tools that can help detect overall health 
and wellbeing are necessary in adolescents living with obesity (7-9).    
Body mass index (BMI) is currently the most commonly used measure to diagnose obesity in 
adolescents. BMI is calculated by dividing weight by height squared (kg/m2). In pediatrics, children or 
adolescents aged 2 to 19 with BMI in the 85th to 94th percentile for their age and sex would be classified 
as overweight, while with BMI ≥95th percentile they would be classified as having obesity 
(https://www.cdc.gov/growthcharts/). Although BMI is practical and inexpensive, in recent years, it has 
been heavily criticized due to its overly simplistic approach to determining severity and 
biopsychosocial impacts of obesity (10, 11), its limitations in pediatric populations (12), and its 
potential to misdiagnose overweight or obesity (13-16). Two adolescents with the same BMI can have 
very different body compositions and health status. In fact, some adolescents with elevated BMI may 
be metabolically healthy (17, 18). The classification of obesity by BMI does not provide information 
on how excess adiposity may negatively impair health and wellbeing of an adolescent. The World 
Health Organization defines health, as “a state of complete physical, mental and social well-being and 
not merely the absence of disease or infirmity” (19). Having access to a clinical staging system of 
obesity that allows healthcare professionals to better determine the health and wellbeing of adolescents 
with obesity is necessary for guiding clinical care.    
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Created in 2016, the Edmonton Obesity Staging System for pediatrics (EOSS-P) is the first 
assessment tool created to classify pediatric obesity by weight-related comorbidities and weight-
management barriers. EOSS-P takes into account the patient’s metabolic health, mental health, 
biomechanical health, and social milieu (4Ms) to determine the severity of obesity and provide 
prognostic information and to help guide future clinical care. EOSS-P was not intended to replace BMI 
percentile, but rather to complement it by improving risk stratification of pediatric obesity. EOSS-P is 
based on the Edmonton Obesity Staging System (EOSS) for adults and is carefully tailored for usage in 
pediatrics (10). The obesity stages of EOSS for adults have been shown to be better predictors of 
mortality than BMI-based obesity classifications (6, 20). Adults with higher EOSS stages (e.g. stages 2 
and 3) require longer weight-management treatment-time than adults with lower EOSS stages (e.g. 
stages 0 and 1) to achieve similar weight loss outcomes (21). EOSS for adults is being used as an 
assessment tool in bariatric clinics in Canada, Germany and Brazil (22). To date, no studies have 
evaluated how EOSS-P is associated with health and wellbeing in children or adolescents with obesity. 
In order for EOSS-P to help guide clinical care, it must be studied in a pediatric sample with obesity. 
Previous studies evaluating EOSS for adults used mortality risk as an adverse health outcome. 
However, mortality due to chronic disease in adolescents is extremely low, we chose instead to focus 
on markers of future morbidity and mortality. QOL, cardiorespiratory fitness, and muscular strength are 
feasible measures known to be good representations of health and wellbeing in adolescents (23, 24). 
QOL is consistently lower in populations with chronic disease (25), and promotion of QOL has been 
identified as an over-arching public health goal from Healthy People (United States governmental 
public health organization) 2000, 2010, and 2020 (26). Cardiorespiratory fitness is the capacity of an 
individual to carry out long, strenuous exercise (27). Cardiorespiratory fitness has been proposed by the 
American Heart Association for routine assessment in clinical practice because of its strong association 
with cardiovascular disease and all-cause mortality (28). Higher levels of cardiorespiratory fitness and 
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physical activity are associated with significantly lower risk of mortality in individuals with obesity (5). 
Muscular strength, which is a component of muscular fitness, refers to “the ability to carry out maximal 
force” against a resistance (29). Cardiorespiratory and muscular fitness are consistently lower in 
populations with chronic diseases and are independently associated with metabolic risk factors in 
adolescents (23, 30). Muscular strength is associated with higher insulin sensitivity in adolescents (31), 
and higher strength is a strong predictor of lower mortality and longer life expectancy in adults (32). 
QOL, cardiorespiratory fitness, and muscular strength are, therefore, good measures of general health 
and wellbeing and a single assessment tool that demonstrates associations with these measures in a 
population of adolescents with obesity would be optimal to help healthcare professionals guide clinical 
care for their patients. 
The purpose of this study was to investigate EOSS-P and BMI percentile regarding their 
associations with QOL, cardiorespiratory and muscular strength in a sample of adolescents with 
overweight and obesity. We hypothesized that both EOSS-P and BMI percentile would be negatively 
associated with QOL, cardiorespiratory fitness and muscular strength. To our knowledge, this is the 






This is a secondary data analysis from the Healthy Eating, Aerobic and Resistance Training in 
Youth (HEARTY) randomized controlled trial completed between 2005 and 2011 (33), for which 
primary results have been previously reported (34). At baseline, participants completed a series of 
assessments that were used to establish EOSS-P scores. QOL, cardiorespiratory fitness, and muscular 
strength were also assessed at baseline.  
Participants 
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Baseline participants (N=304) included were physically inactive post-pubertal adolescents 
(Tanner stage 4-5 (35, 36)) with overweight or obesity aged 14-18 years old. Five participants were 
lacking mental health data so the final analysis included N=299. Participants were eligible for the study 
if their BMI was ≥95th percentile for their age and sex or ≥85th percentile 
(https://www.cdc.gov/growthcharts/) with an additional risk factor for diabetes or cardiovascular 
disease. Twenty-two (7%) participants had overweight, while n=282 (93%) had obesity. Our sample 
had a mean BMI percentile of 97.8, ranging from 87.2 to 99.8. Informed consent was obtained from 
participants and from a parent or legal guardian of participants under 16. The Research Ethics Boards 
at the Children’s Hospital of Eastern Ontario and the Ottawa Hospital approved this study. 
EOSS-P 
 
EOSS-P categorizes obesity using a 4-point staging system ranging from stage 0 (no risk), stage 
1 (mild risk), stage 2 (moderate risk), and stage 3 (severe risk). Using EOSS-P guidelines from the 
original EOSS-P tool development (10), a team consisting of five experts (two clinical pediatric 
psychologists, one pediatric endocrinologist, and two obesity researchers) was consulted to create the 
EOSS-P algorithm applicable for assessment of HEARTY participants (Table 1). A primary evaluator 
(GAK) staged all participants, and a secondary evaluator (ML) evaluated a random sample (n=30, 10% 
of total sample) for interrater reliability. The interrater Cronbach’s alpha was 0.959, indicating near-
perfect agreement. Information on mental health questionnaires used in HEARTY that were specific to 
the EOSS-P algorithm used in this study are provided in a supplementary appendix. 
Cardiorespiratory fitness 
 
A certified exercise physiologist assessed peak oxygen uptake (VO2peak) with indirect 
calorimetry (MOXUS Modular Metabolic System, AEI Technologies Naperville, IL, USA) during a 
maximal treadmill test, the gold standard for measurement of cardiorespiratory fitness (37). During the 
VO2peak test participants were instructed to walk on a treadmill at a progressively increasing incline 
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following the modified Balke and Ware incremental treadmill protocol (38) until volitional fatigue. 




An exercise specialist assessed upper body (bench press) and lower body (leg press) muscular 
strength using 8-repetition maximum (8RM) tests (the maximum weight that could be lifted eight times  
for each exercise while maintaining proper form through the full range of motion).  
Quality of life 
 
HEARTY participants completed the 23-item Pediatrics QOL Inventory 4.0 (PedsQL) (24) as 
part of a larger battery of measures. The PedsQL is divided into four categories including: physical 
functioning (eight items), emotional functioning (five items), social functioning (five items) and school 
functioning (five items). Each item is ranked using a 5-point Likert scale ranging from “Never” to 
“Almost Always”. The total score was used for the analyses.  The PedsQL is a reliable and feasible 
questionnaire that has been validated to assess QOL in a sample of adolescents with obesity (3, 39). 
This validation study showed that PedsQL had an internal consistency alpha of 0.80 (39).  
Statistical analysis 
 
Baseline characteristics were compared between EOSS-P stages using ANOVA.  We created 
general linear models to determine associations of EOSS-P and BMI percentile with QOL, 
cardiorespiratory fitness, and muscular strength. We adjusted for age, and sex in our analysis. 
Confounding variables were determined a priori. Bonferroni’s post hoc test was used to assess 
differences between EOSS-P stages. Mean PedsQL scores were compared for each successive EOSS-P 
stage using the Student’s T-test. All analyses were conducted SPSS Statistics for Windows, version 24 
(IBM Corp., Armonk, N.Y., USA). 





Table 2 displays the baseline characteristics of the 299 participants included in our study. The 
sample included a total of 88 (29%) males and 211 (71%) females. The EOSS-P distribution of our 
sample in stage 0 was n=7 (2%), stage 1 n=116 (39%), stage 2 n=146 (49%), and in stage 3 n=30 
(10%). The mean BMI of the overall sample was 34.6  0.5 kg/m2, and mean BMI percentile was 97.8 
 1.9. There were no significant baseline differences in age, BMI, BMI percentile, VO2peak, treadmill 
time, leg press, and bench press between the four EOSS-P stages except for QOL (p<0.001).  
Table 3 shows parameter estimates for EOSS-P, BMI percentile, sex, and age for each outcome, 
including QOL, cardiorespiratory fitness, muscular strength. Since only 2.5% of our sample was stage 
0, we grouped stage 0 and 1 together for our analysis. In all general linear models, stage 0/1 was used 
as the reference variable for EOSS-P, and female sex was the reference variable for sex. 
Quality of life 
 
Three participants were missing QOL assessments. For QOL as the outcome, there were 
significant differences between stage 0/1 and stage 2 (p<0.001), and between stage 0/1 and stage 3 
(p<0.001). BMI percentile showed no significant association with QOL. The greatest differences in 
QOL scores were found between stage 0/1 and stage 3. Post-hoc analysis revealed significant 
differences between stages 2 and 3 (see figure 1). Sex was associated with QOL, with males having 
higher QOL scores (p=0.008) (see Table 3). 
Cardiorespiratory fitness 
 
There were no significant differences in VO2peak between EOSS-P stages (p=0.32). BMI 
percentile was negatively associated with VO2peak (p<0.001), with a decrease of 1.05 mlO2/kg/min for 
each unit increase in BMI percentile.  
Cardiorespiratory fitness and BMI percentile are outcome variables measured relative to a 
person’s body weight, thus we created similar models replacing VO2peak with VO2peak treadmill time 
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(time to reach VO2peak) as the outcome, to account for body weight. We found no significant 
differences in treadmill time between EOSS-P stages (p=0.31). BMI percentile was negatively 
associated with treadmill time (p<0.001). There were sex differences in treadmill time (p<0.001), with 
males taking on average 97 seconds more time to reach VO2peak. Age showed no significant association 
with treadmill time (see Table 3). 
Muscular strength  
 
Fifty-one participants were missing muscular strength assessments. There were no associations 
found between EOSS-P and upper body strength (p=0.71). BMI was positively associated with upper 
body strength (p=0.029), with an increase of 0.8 kg per unit of BMI percentile. Males had significantly 
greater upper body strength than females (p<0.001). Age was positively associated with upper body 
strength (p=0.011).   
There were no associations found between EOSS-P and lower body strength (p=0.94). BMI 
percentile showed a positive association with lower body strength (p=0.003), with an increase of 4.0 kg 
per unit of BMI percentile. Males had significantly greater lower body strength than females (p<0.001). 
Age was positively associated with lower body strength (p=0.001) (see Table 3). 
DISCUSSION 
 
The purpose of this study was to contrast EOSS-P and BMI percentile regarding their associations 
with QOL, cardiorespiratory fitness and muscular strength. We hypothesized that both EOSS-P and 
BMI percentile would be negatively associated with QOL, cardiorespiratory fitness and muscular 
strength. Our results showed that EOSS-P was associated with QOL, but not associated with 
cardiorespiratory fitness or muscular strength. In contrast, BMI percentile was not associated with 
QOL, but was negatively associated with cardiorespiratory fitness and positively associated with 
muscular strength. The contrasting findings between EOSS-P and BMI percentile provide insight on 
how they can complement each other.  
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Previous EOSS studies have only been conducted in adults. Padwal et al. (2011), found no 
observable differences in mortality-risk between stages 0 and 1, but found elevated mortality-risk in 
stage 2, and more so in stage 3. Kuk et al (2011), observed individuals with normal weight as the 
reference group, and found stage 0/1 to have no difference in all-cause mortality, but stage 2 and stage 
3 had elevated risks of all-cause of mortality. Consistent with these prior studies in adults, stage 2 had 
lower QOL than stage 0/1, and stage 3 had lower QOL than stage 0/1 and 2.  
QOL, and all-cause mortality are associated with individual’s psychological, social and physical 
health (6, 20, 25, 39). Conversely, cardiorespiratory and muscular fitness are predominantly reflective 
of physical health (23, 28, 40). Since EOSS-p is a tool that reflects 4Ms (metabolic health, mental 
health, biomechanical health, and social milieu), this may explain, this may explain why we did not 
find an association between EOSS-P and cardiorespiratory fitness or muscular strength. Considering 
the evidence surrounding cardiorespiratory fitness and muscular strength as important markers of 
health (23, 28, 40), and the lack of association between EOSS-P and fitness, it is plausible that EOSS-P 
is lacking physical activity and/or fitness components. Our study, however, treated cardiorespiratory 
fitness and muscular strength as baseline outcomes. It would be advantageous to conduct follow-up 
longitudinal studies utilizing EOSS-P with adolescents and measuring long-term outcomes such as 
cardiovascular disease incidence and all-cause mortality. 
One review pooled data from 13 studies in pediatric populations, and found a negative 
association between BMI and QOL (via PedsQL) (r= –0.7, p=0.008) (41). The lack of association 
between BMI percentile and QOL in our study might be attributed to the narrow range of BMI 
percentiles in this sample of adolescents with high BMIs, as found in other studies with adolescents 
with severe obesity (42). Although we also had participants with overweight, they comprised only 
7.4% of our sample and required an additional weight-related comorbidity to qualify for this study. We 
observed a negative association between BMI percentile and cardiorespiratory fitness. Conversely, 
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BMI percentile was positively associated with upper and lower muscular strength. BMI is strongly 
associated with percent body fat at the population level (13, 16), however it is a poor predictor of body 
fat at the individual level (13, 16). Although BMI is a crude measure of body composition (16) and has 
received criticism in being an over-simplistic approach of determining pediatric obesity (12), it gives 
an indication of relative body size. A greater BMI would correspond to more fat mass and/or fat free 
mass. Excess body fat has already been shown to be closely and negatively associated with 
cardiorespiratory fitness (30), while muscle mass (a major component of fat free mass) has been shown 
to be positively associated with muscular strength (43, 44). This can explain the positive association 
between BMI percentile and muscular strength, and its negative association with cardiorespiratory 
fitness.  
Practical applications 
Many healthcare professionals are ill-equipped to address the needs of children and youth with 
obesity (45). EOSS-P and its 4Ms (metabolic health, mental health, biomechanical health, and social 
milieu) are intended to provide a more comprehensive individualized health risk assessment of a patient 
with obesity than the currently used anthropometric measurements (i.e. BMI). EOSS-P provides 
healthcare professionals with a structured framework containing a checklist of assessments on weight-
related comorbidities, and barriers to weight management that can help guide weight-management 
plans for their patients (10). A recent study investigated the perceived usefulness of the EOSS-P across 
various levels of care provided for pediatric patients with obesity (46).  They found that EOSS-P was 
ranked as a very useful tool by 52.6% and somewhat useful by 31.6% from a sample of 57 referring 
healthcare professionals. Thus, the EOSS-P provides an improved and feasible methodology for 
stratifying health risk in pediatric obesity.  
Obesity Canada refers to obesity as a “progressive chronic disease which is characterized by 
abnormal or excessive fat accumulation that may impair health”. Given this definition of obesity as a 
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“progressive chronic disease”, EOSS-P would offer healthcare professionals a staging system to 
monitor the progression of obesity, analogous to staging of cancer.  Our study showed that participants 
with similar BMI, or BMI percentile can present across the EOSS-P staging spectrum. Assessing BMI 
with EOSS-P would provide a more comprehensive health risk assessment, and help distinguish 
individuals with similar BMIs at different stages in their obesity.  
Our findings indicate that as EOSS-P stages increase, QOL of a patient tends to decrease. Although 
it is reasonable to believe that improvements in EOSS-p stage would likely signify improvements in 
QOL, this issue warrants further investigation. Our results also showed a lack of cross-sectional 
associations between EOSS-P, cardiorespiratory fitness and muscular strength. Since muscular strength 
and cardiorespiratory fitness are important physical health outcomes, one might consider measuring 
physical activity or fitness to improve assessment of obesity-related health risk in addition to EOSS-P 
in adolescents. However, determining if a physical activity or fitness assessment will improve obesity-
related health risk remains to be investigated.   
The American Heart Association in 2016 issued a scientific statement attesting to cardiorespiratory 
fitness being a vital sign that should be assessed routinely in clinical practice (28). It stated that the 
addition of cardiorespiratory fitness to other risk factors improves the classification of risk for adverse 
outcomes (28). Considering the cost, time, and requirement for additional personnel to conduct a 
fitness test, accelerometers or a physical activity and sedentary behaviour questionnaire might be more 
easily implemented or added to EOSS-P instead. However, it is important to acknowledge limitations 
with questionnaires, in that they may not provide the same quality of information as a fitness test, or an 
objective measure of physical activity and sedentary time would (i.e. accelerometry). Physical activity 
plays a pivotal role in the development of weight-related comorbidities (47) and it has already been 
suggested to include questions on physical activity in routine healthcare assessments (48).  
Limitations 
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We acknowledge several limitations of our study. Firstly, the sample was mainly Caucasian 
(72%) and female (71%), which would affect the generalizability of the results to Canadian 
adolescents. Secondly, mental health assessments were derived from self-report questionnaires. Our 
team of five experts came to a consensus on how to interpret a set of validated questionnaires for 
EOSS-P staging (see Table 1). It is recommended that a clinical interview be done by a health care 
professional for the EOSS-P mental health assessment as opposed to solely depending on self-report 
questionnaires to make a diagnosis. Thirdly, this is a secondary data analysis on variables that were not 
intended specifically for EOSS-P, thus we had limited data on mechanical and social milieu categories. 
The limited data may have caused underestimation of EOSS-p scores. Lastly, this study was a cross-
sectional design, which limits the causal inferences regarding associations.   
Future studies should assess EOSS-P through a clinical evaluation of the 4Ms (metabolic health, 
mental health, biomechanical health, and social milieu), as is intended for the EOSS-P. With this 
approach, researchers will have a better understanding of the EOSS-P because all EOSS-P variables 
would be measured. Future studies should also assess EOSS-P across various Tanner stages, as there 
are considerable physiological differences among people at different Tanner stages (35, 36). 
Longitudinal health outcomes, such as development of cardiovascular disease, all-cause mortality, 
EOSS stage in late adulthood, in larger samples are of interest to understand how EOSS-P can predict 
risk of obesity related comorbidities over time.  
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Note:  ǂ, indicates our HEARTY diagnostic criteria for this specific EOSS-P variable 
 LDL-C: low density lipoprotein - cholesterol 
HDL-C: high density lipoprotein - cholesterol 
ALT: alanine transaminase 
CDI: Children’s Depression Inventory 
MBSRQ: Multidimensional Body–Self Relations Questionnaire 
DEBQ: Dutch Eating Behavior Questionnaire 
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Table 1. EOSS-P staging criteria. 
 
Note:  ǂ, indicates our HEARTY diagnostic criteria for this specific EOSS-P variable 
 LDL-C: low densitry lipoprotein - cholesterol 
HDL-C: high density lipoprotein - cholesterol 
ALT: alanine transaminase 
CDI: Children’s Depression Inventory 
MBSRQ: Multidimensional Body–Self Relations Questionnaire 
DEBQ: Dutch Eating Behavior Questionnaire  
ADHD:  attention deficit hyperactivity disorder 
Stage 1: Presence of subclinical obesity-related risk factors 
Acanthosis Nigricans 
Pre-hypertension: Systolic or Diastolic 
Impaired glucose tolerance (7.8-11.0 mmol/L) and/or Impaired fasting glucose (6.1-6.9 mmol/L) 
LDL-C and/or Non-HDL-C 3.4-4.1 mmol/L 
HDL-C 0.8-1.03 mmol/L 
Triglycerides 1.5-4.0 mmol/L 
ALT 1.5-2.0x normal values 
Mild depression or anxiety that does not interfere with functioning  
ǂ (Diagnosis of anxiety of depression greater than two years ago with no current treatment) or (CDI 
score  in 84th-92th percentile (above average)) 
Mild body image preoccupation/concern  
ǂ (MBSRQ Appearance Evaluation mean score 2-2.99 (neither agree of disagree to mostly disagree)) 
Mild emotional/binge eating (occasional)  
ǂ (1x/month to <1x/week) or (DEBQ emotional eating subscale mean score 3-4 (sometimes to often)) 
ADHD and/or learning disability 
Caregiver has or is recovering from medical/physical, mental health and/or substance-use problems 
Stage 2: Presence of OB-related chronic diseases/health issues 
Type 2 Diabetes without diabetes-related complications 
Hypertension: Systolic or Diastolic 
LDL-C or Non-HDL-cholesterol >4.2 mmol/L 
HDL-Cholesterol  <0.8 mmol/L 
Triglycerides >4.0 mmol/L 
ALT 2-3x normal values 
Polycystic ovarian syndrome 
Gastroesophageal reflux disease 
Major depression or anxiety disorder  
ǂ (Diagnosis of anxiety of depression within two years ago) or (on pharmacological treatment) or (CDI 
score in 93rd-97th percentile (much above average)) 
Moderate binge eating (frequent)  
ǂ (1x/week to 6x/week) or (DEBQ Emotional Eating subscale 4.01 to 5 (often to always)) 
Significant body image disturbance  
ǂ (MBSRQ Appearance Evaluation subscale mean score 1 to 1.99) or (mostly disagree to definitely 
disagree)) 
Stage 3: Presence of established chronic diseases/health issues 
Type 2 Diabetes with diabetes-related complications or HbA1c ≥ 8 
Elevated lipids requiring pharmacotherapy 
ALT >3x normal limits and/or liver dysfunction 
Hypertension on pharmacotherapy 
Uncontrolled hypertension on pharmacotherapy 
Uncontrolled psychopathology  
ǂ (CDI score greater than 98th percentile (very much above average)) 
Sever binge eating (daily)  
ǂ (Bing eating 7x/week) 
Self/physical loathing 
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Table 2. Baseline participant characteristics.  
 
  Total Sample 
(N=299) 
Stage 0 (n=7) Stage 1 (n=116) Stage 2 (n=146) Stage 3 (n=30) 
      
  N (%) N (%) N (%) N (%) N (%) 
Male 88 (29.4) 1 (14.3) 33 (28.4) 46 (31.5) 8 (26.7) 
Female 211 (70.6) 6 (85.7) 83 (71.5) 100 (68.5) 22 (73.3) 
      
  Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Age (years) 15.6 (1.4) 15.9 (1.3) 15.6 (1.4) 15.6 (1.3) 15.8 (1.5) 
BMI (kg/m2) 34.6 (4.5) 35.4 (6.2) 34.0 (3.9) 35.2 (4.8) 34.2 (4.1) 
BMI percentile 97.8 (1.9) 97.5 (1.9) 97.8 (1.5) 97.9 (2.0) 97.6 (2.3) 
PedsQL  70.4 (13.8)* 81.1 (10.1) 75.4 (11.4) 69.1 (13.1) 55.4 (13.0) 
VO2peak (mlO2/kg/min) 30.4 (5.0) 31.6 (7.5) 30.7 (4.7) 30.1 (5.2) 29.8 (4.9) 
VO2peak treadmill time 
(s) 
993.3 (177.5) 1045.7 (184.2) 1009.0 (178.1) 980.7 (180.3) 982.5 (161.0) 
Bench press (kg) 22.0 (11.6) 32.7 (17.7) 28.1 (10.7) 28.1 (12.0) 26.3 (11.5) 
Leg press (kg) 102.3 (37.7) 123.0 (52.9) 101.7 (34.4) 102.9 (39.1) 98.2 (41.3) 
 
 
Note: * p<0.001 
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Treadmill time (s) 
 
Seated bench press (kg) 
 
Leg Press (kg) 
(n=296) (n=299)   (n=299) (n=248)   (n=248) 
 B Std. Error Sig. 
 B Std. Error Sig. 
 B Std. Error Sig. 
 B Std. Error Sig. 
 B Std. Error Sig. 
                     
Stage 0/1 Reference  Reference  Reference  Reference  Reference 
Stage 2 -6.85 1.52 <0.001  -0.67 0.54 0.22  -30.90 34.92 0.39  -0.84 1.31 0.52  -0.66 4.56 0.89 
Stage 3 -20.14 2.51 <0.001  -1.08 0.89 0.23  -30.84 20.99 0.14  -1.49 2.13 0.49  -2.54 7.43 0.73 
                    
BMI  
percentile -0.10 0.42 0.82 
 -1.04 0.15 <0.001  -22.61 5.79 <0.001  0.83 0.38 0.029  3.99 1.32 0.003 
                    
Female Reference  Reference  Reference  Reference  Reference 
Male 4.52 1.70 0.008  5.28 0.60 <0.001  96.94 23.59 <0.001  12.25 1.45 <0.001  26.68 5.03 <0.001 
                    
Age  
(per year) -0.89 0.52 0.09 
 -0.33 0.19 0.08  -10.85 7.25 0.14  1.15 0.45 0.011  5.35 1.56 0.001 
 
Note: Parameter estimates (B) are the change in the dependent variable associated with each unit increase of the independent variable, while 
all other variables are constant.  
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Figure 1. Graph demonstrating QOL at each EOSS-P stage. 
 










   
56 
 
3.1 Additional results 
 
 This ‘additional results’ section includes all analyses with outcomes assessed at 6-months. These 
outcomes include: 6-month QOL, 6-month cardiorespiratory fitness, 6-month muscular fitness, and 
adherence to exercise. Tables 3, 4, and 5 show results from the general linear models for EOSS-p, BMI 
percentile, sex, age, group assignment, and baseline assessment of the outcome variable.  
From the overall N= 304, five participants were lacking EOSS-p mental health data so the final 
analysis included N= 299. Table 2 displays the baseline characteristics of the 299 participants included 
in our study. The sample included a total of 88 (29%) males and 211 (71%) females. The EOSS-p 
distribution of our sample in stage 0 was n= 7 (2.3%), stage 1 n= 116 (38.8%), stage 2 n= 146 (48.8%), 
and in stage 3 n= 30 (10%).  Since only 2.5% of our sample was stage 0, we grouped stage 0/1 for our 
analysis. In all general linear models, stage 0/1 was used as the reference variable for EOSS-p, females 
was the reference variable for sex, and control group is the reference variable for group assignment.  
 
3.1.1 6-month QOL   
 
 For 6-month QOL as the outcome, there were no significant associations with EOSS-p (p=0.395), 
nor with BMI percentile (p=0.344). Sex (p=0.170) and group assignment (p=0.214) showed no 
associations with 6-month QOL. There was a trend of association between age and 6-month QOL 
(p=0.064).  Baseline QOL was associated with 6-month QOL (p<0.001, F=156.62, Eta2=0.44).  
 
3.1.2 6-month VO2peak 
 
 EOSS-p (p=0.001, F=7.43, Eta2=0.01), BMI percentile (p<0.001, F=15.98, Eta2=0.08), sex 
(p<0.001, F=18.55, Eta2=0.09), group assignment (p=0.001, F=5.91, Eta2=0.09) and baseline VO2peak 
(p<0.001, F=98.45, Eta2=0.35) showed significant associations with 6-month VO2peak. Age showed no 
significant associations with 6-month VO2peak (p=975). Parameter estimates showed significant 
differences between EOSS-p stage 0/1 and stage 3 (p<0.001), but not between EOSS-p stage 0/1 and 
stage 2 (p=0.921). Bonferroni’s post-hoc analysis showed significant differences between stage 2 and 
stage 3 (p=0.001).  
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Cardiorespiratory fitness and BMI percentile are outcome variables measured relative to a 
person’s body weight, thus we created similar models replacing VO2peak with VO2peak treadmill time (time 
to reach VO2peak) as the outcome, to account for body weight. 6-month treadmill time showed significant 
associations with EOSS-p (p=0.044), BMI percentile (p=0.006), group assignment (p=0.001) and 
baseline treadmill time. Parameter estimates showed significant differences between EOSS-p stage 0/1 
and stage 3 in treadmill time (p=0.013).  
 
3.1.3 6-month upper body strength 
 
 BMI percentile (p=0.002, F=10.37, Eta2=0.07), sex (p=0.007, F=7.49, Eta2=0.49), group 
assignment (p<0.001, F=13.83, Eta2=0.22), and baseline upper body strength (p<0.001, F=151.80, 
Eta2=0.51) were associated with 6-month upper body strength. EOSS-p and age were not associated with 
6-month upper body strength (p=0.693, and p=0.743 respectively).   
 
3.1.4 6-month lower body strength 
 
 BMI percentile (p=0.005, F=8.04, Eta2=0.05), group assignment (p<0.001, F=10.57, Eta2=0.18), 
and baseline lower body strength (p<0.001, F=91.86, Eta2=0.39) show significant associations with 6-
month lower body strength. EOSS-p, age, and sex showed no significant associations with lower body 




 Group assignment is the only variable showing significant associations with adherence (p<0.001, 
F=80.38, Eta2=0.45). Age shows a trending association with adherence (p=0.058). EOSS-p, BMI 
percentile, and sex show no association with adherence (p>0.05). 
 
 









4.1 Summary of main findings 
 
The purpose of this thesis was to contrast EOSS-p and BMI percentile regarding their associations 
with QOL, cardiorespiratory fitness, muscular strength, and adherence. Baseline outcomes have been 
discussed at length in Manuscript 1. This discussion will focus on 6-month outcomes (ie. 6-month QOL, 
6-month cardiorespiratory fitness, 6-month muscular strength and adherence). Our results showed that 
EOSS-p was only associated with 6-month cardiorespiratory fitness, and showed no associations with 6-
month QOL, 6-month upper and lower muscular strength, and adherence to exercise. BMI percentile 
showed negative associations with 6-month cardiorespiratory fitness, positive associations with 6-month 
upper and lower muscular strength, and no associations with QOL or adherence.  
The majority of our sample was in stage 2 (49%), then stage 1 (39%), then stage 3 (10%), then stage 
0 (2%). Studies examining EOSS in adults also found stage 2 to be the most common EOSS stage 
consisting of 53%, 70%, 82%, and 84% of their sample (6, 65-68). Another EOSS study had an equivalent 
number of adult participants in stage 2 and 3 (31.2% and 31.6% respectively) (69).  This evidence 
suggests that the majority of adolescents and adults with obesity are classified as having stage 2. Our 
sample represents a community sample of inactive post-pubertal adolescents with obesity, with several 
exclusion criteria that may underestimate the distribution of EOSS-p stages in the general population of 
adolescents with obesity.  
4.2 EOSS-p and BMI percentile with adherence 
 
The results confirm the hypothesis that both EOSS-p and BMI percentile were not associated 
with adherence to the HEARTY exercise intervention. In addition, age, sex, and percent body fat were 
also not associated with adherence. Although studies investigating predictors of adherence to weight-
management interventions in adolescents with obesity have not been identified, a review has explored 
attrition to paediatric weight-management programs in children and adolescents with obesity (47). 
Attrition is defined as dropping out of the agreed treatment or intervention. Skelton et al. 2011 identified 
that BMI has been shown to be a predictor of attrition in some pediatric obesity studies (74-76), but not 
in others (77, 78). A systematic review focusing on adulthood obesity, found lower baseline BMI, lower 
depression, stress, and anxiety to be predictors of adherence to weight management programs (46). 
Although EOSS-p contained many of the predictors of adherence for adulthood obesity listed above, it 
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is possible that predictors for adherence in adults may not reflect predictors of adherence in adolescents 
with obesity. Unlike adults, children and adolescents are dependent on their parents and/or guardians. 
Lower caregiver-related quality of care (79), and single parent households (76) have been identified as 
predictors of attrition in adolescents with obesity.  The social milieu category of EOSS-p considers 
caregiver-related quality of care, and single-parent-households, however, we were limited in our 
evaluation of social milieu with the HEARTY participants. Previous reviews investigating adherence and 
attrition in adults (46) and pediatric (47) samples respectively, were investigating multidisciplinary 
weight management programs consisting of a combination of diet, exercise and other behaviour-focused 
strategies. The HEARTY trial was largely an exercise intervention, with a minor dietary component, thus 
it would be beneficial to investigate if EOSS-p can predict adherence to a multidisciplinary weight-
management intervention in a clinical setting.  
 
4.3 EOSS-p and 6-month QOL, cardiorespiratory fitness and muscular strength 
 
It was hypothesized that EOSS-p would be negatively associated with 6-month QOL, 
cardiorespiratory fitness and muscular strength. EOSS-p was not associated with 6-month QOL, or 
muscular strength, but it was associated with 6-month cardiorespiratory fitness. We found that 
participants in stage 3 had significantly lower 6-month cardiorespiratory fitness than those in stage 0/1 
and 2. A previous study showed that adults with higher EOSS stages (stage 2 and 3) required longer 
weight management intervention times to achieve similar weight loss outcomes (65). Canning et al.’s 
(2015) and our results suggest that perhaps participants in stage 3 do not benefit as efficiently from diet 
and exercise interventions than their counterparts in lower EOSS stages with lower health risks. I 
speculate that the weight lost from a diet and exercise intervention might be due to a decrease in percent 
body fat. A decrease in body fat is associated with increasing cardiorespiratory fitness (7, 50, 70). In my 
study, adolescents with obesity received the same duration of intervention, but stage 3 showed smaller 
improvements in cardiorespiratory fitness. To determine if the same trends in my results were due to the 
intervention and not just time, I conducted a supplementary analysis (see Table 6 – 11) within the control 
group only, and one for the exercise intervention group only. I found that only stage 3 participants in the 
exercise groups had lower 6-month cardiorespiratory fitness, while stage 3 participants in the control 
groups showed no differences in 6-month cardiorespiratory fitness compared to stages 0/1, and 2. 
Arguably, this evidence suggests longer, more intensive, or different interventions may be required for 
teens with obesity in stage 3 with more adverse co-morbidities and health risks. Improvements in 
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cardiorespiratory fitness are desired outcomes in adolescent obesity, therefore using EOSS-p can be 
practical for health-care professionals when determining treatment duration for patients with adolescent 
obesity. More research is needed to determine how the EOSS-p can be used to inform treatment time or 
other specific intervention designs/ components; especially for participants in more severe health risk 
stages (i.e. stage 3).  
 
4.4 BMI with 6-month QOL, cardiorespiratory fitness and muscular strength 
 
It was hypothesized that BMI percentile would be negatively associated with QOL, 
cardiorespiratory fitness and muscular strength. BMI percentile was not associated with 6-month QOL. 
Previous studies found that as BMI decreases over time, QOL increases proportionately in adolescents 
(71). In a review analyzing 13 studies, a negative association was found between BMI and quality of life 
(via PedsQL) (r= –0.7, p=0.008) (72). The lack of association between BMI percentile and QOL in our 
study is likely due to the truncated BMI range in this sample of adolescents with elevated BMI’s. 
Although a portion of our sample had overweight, they only consisted of 7.4% of our total sample and 
possessed a weight-related comorbidity. Furthermore, as hypothesized, we found a negative association 
with BMI percentile and 6-month cardiorespiratory fitness; however, we found a positive association 
between BMI percentile and muscular strength. These results are contradictory with regards to health 
outcomes. It can be speculated that since BMI percentile does not distinguish between fat mass and 
muscle mass, a greater BMI percentile can reflect greater fat mass and/or muscle mass. It is well known 
that fat mass is closely linked with cardiorespiratory fitness (7, 50, 70), while muscle mass is closely 
linked with muscular strength (73). This could account for BMI percentile’s contradicting associations 
with cardiorespiratory fitness and muscular strength. This contradicting finding reinforces the notion that 
BMI percentile should not be used as a sole measure of determining health risk.  
 
  





Obesity affects a third of the Canadian pediatric population, and several adverse health risks can 
ensue. The optimal assessment tool to determine severity and risk stratification of pediatric obesity is 
warranted. The purpose of this thesis was to compare EOSS-p with BMI percentile, in their associations 
with QOL, cardiorespiratory fitness, muscular strength, and adherence to exercise. We found that as QOL 
decreases as EOSS-p stages increase. Although baseline EOSS-p was not associated with baseline 
cardiorespiratory of muscular fitness, EOSS-p stage 3 had significantly lower improvements in 
cardiorespiratory fitness after 6-months than other stages after the HEARTY exercise intervention. 
However, BMI percentile was not associated with QOL or adherence, but was negatively associated with 
cardiorespiratory fitness and positively associated with strength. Our findings suggest that EOSS-p can 
be beneficial in determining relative QOL according to stage, and that stage 3 may require a longer 
duration of intervention or a different type of intervention to see health improvements. BMI percentile, 
showed contradictory associations with our health outcomes, highlighting flaws when determining 
severity of obesity according to BMI percentile. EOSS-p can improve risk stratification of children and 
adolescents with obesity rather than the traditional BMI percentile method. This is the first study to 
investigate the relationship of EOSS-p with health outcomes in pediatric obesity. More research is 
warranted to determine the long-term relationships between EOSS-p and health outcomes, and its ability 
to predict adherence and attrition to other interventions with children and adolescents living with obesity.  
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Figure 2: Flow diagram of HEARTY study overview 
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Table 1: Modified HEARTY testing timeline (49) 
Variable 
  






screening  visit 1 visit 2 visit 3  visit 4   6-month 
Inclusion/exclusion criteria X             
Informed consent    X           
Medical history   X           
Complete physical exam   X           
Total cholesterol     X         
HDL-C     X         
Triglycerides     X         
LDL-C     X         
Liver enzymes (AST/ALT)     X         
Serum Testosterone     X         
Hemoglobin A1C     X         
OGTT     X         
Mental health 
questionnaires (CDI & 
MBSRQ-AS)     X         
QOL questionnaire 
(PedsQL4.0)     X       X 
VO2peak         X   X 
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Table 2: EOSS-p staging algorithm for HEARTY trial 









0 (no) stage 0 
  1 (yes) stage 1 
      
        
  
systolic blood 
pressure systolic <90th percentile stage 0 
    (use this for <18) 
90th to <95th percentile or 
≥120/80 mm Hg stage 1 
      
95th to 99th percentile plus 5 
mm Hg / >99th percentile stage 2 
          
      <120 mmHg stage 0 
    (use this for 18+) 120 to 139 mmHg   stage 1 
      ≥140 mmHg   stage 2 
          
  
diastolic blood 
pressure diastolic <90th percentile stage 0 
    (use this for <18) 
90th to <95th percentile or 
≥120/80 mm Hg stage 1 
      
95th to 99th percentile plus 5 
mm Hg / >99th percentile stage 2 
          
      <80 mmHg stage 0 
    (use this for 18+) 80 to 89 mmHg stage 1 
      ≥90 mmHg stage 2 
          
  triglycerides triglicer >1.5 stage 0 
      1.5-4 stage 1 
      >4.0 stage 2 
          
  fasting glucose preglucose <6.1 stage 0 
      6.1 - 6.9 stage 1 
      ≥7 (T2D) stage 2 
          
  glucose tolerance postglucose <7.8 stage 0 
      7.8 - 11 stage 1 
      >11 stage 2 
          
  Low density 
lipoprotein - 
ldl <3.4 stage 0 
    3.4-4.1 stage 1 
    ≥ 4.2 stage 2 
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  cholesterol (LDL-
c) or non-HDL-c  
      
  non-HDL-c <3.35 stage 0 
  = totchol - hdl 3.35-4.14 stage 1 
      ≥ 4.15 stage 2 
          









>1.03 stage 0 
  0.80-1.03 stage 1 
  <0.80 stage 2 
      














alt normal stage 0 
    1.5-2.0x normal values stage 1 
    2.1-3.0x normal values stage 2 
    >3.0x normal values stage 3 
    < 46.5 stage 0 
  (use this for <18) 
46.5 to 62 (for male) / 37.5 to 
50 (for female) stage 1 
    
62.01 to 93 (for male) / 50.01 
to 75 (for female) stage 2 
    
> 93 (for male) / > 75 (for 
female) stage 3 
    < 46.5 stage 0 
  (use this for 18+) 
67.5 to 90 (for male) / 49.5 to 
66 (for female) stage 1 
    
90 to 135 (for male) / 66 to 99 
(for female) stage 2 
    
>135 (for male) / > 99 for 
female) stage 3 




HbA1c     
        
        
    ≥0.08 (T2D) stage 3 
    medcode      
        
          
      
5 to 14 (example for 
medname: lipitor, lipidil, 
monopril/fosinopril, norvasc, 
cozaar) stage 3 
  
polycystic ovarian 
syndrome previnjury     
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PCOS /polycystic ovarian 
syndrome stage 2 
          
Mental Health Binge eating bingfreq  no binge eating stage 0 
    bing time 
1x/month to < 1x/week = 
occasional stage 1 
      
1x/week - 6 x/week = 
frequent stage 2 
      7x/week = daily stage 3 
    DEBQ <39 stage 0 
    emtn 39 to 52 stage 1 
      52.01 to 65 stage 2 
          
  Body Image apev ≥3 Stage 0 
      2-2.99 Stage 1 
      1-1.99 Stage 2 
          
  Anxiety/Depression depress / anxiety/ 





0 (no) and 0 (no) stage 0 
    
1 (yes) and/or 1 (yes)/ 
(diagnosis grater than 2 years 
ago) stage 1 
    
1 (yes) and/or 1 (yes) / 
(diagnosis within last 2 years, 
any treatment within 2 years) stage 2 
        
    CDI_totalscore <84th percentile stage 0 
    use criteria for all 
participants - 
regardless of age 
84th-92th percentile stage 1 
    93th-97th percentile stage 2 
    >98th percentile stage 3 
    
 medcode/ 
medname     
          
      
 20, 21, 22/ if 20 (cipralex, 
seraquil, valproid acid) stage 2 
          
  
ADHD or learning 
disability 
medcode/medname 
    
    
20 / ritalin, stratera, 
dextroamphetamine, concerta, 
dexedrin stage 1 
        
        
    previnjury     
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ADHD / ADD / Learning 
difficulty  stage 1 
        
        
Mechanical GERD Medcode      
    medname     
      20  (pantoloc or ranitidine) stage 2 













meduc / feduc 




3 or 4 stage 0 
2 stage 1 
1 stage 2 
    
parental health m_depress/ 
f_depress / 
m_other / f_other 




0 (no) stage 0 
  1 (yes) stage 1 
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Table 3: Tests of Between-Subjects Effects 




treadmill time  
6-month Seated  
bench press (kg) 
6-month Leg 
 Press (kg)   
6-month  
adherence  
   (n=209) (n=196) (n=196)  (n=156) (n=154) (n=299) 
  F Sig. Eta2 F Sig. Eta2 F Sig. Eta2 F Sig. Eta2 F Sig. Eta2 F Sig. Eta2 
Corrected  
Model 23.45 <0.001 0.52 28.46 <0.001 0.58 12.29 <0.001 0.37 45.18 <0.001 0.74 21.21 <0.001 0.57 31.09 <0.001 0.46 
                   
EOSS-p 0.93 0.40 0.01 7.43 0.001 0.07 3.17 0.044 0.03 0.37 0.69 0.01 1.08 0.34 0.02 0.08 0.92 <0.01 
                   
BMI  
percentile 0.90 0.34 0.01 15.98 <0.001 0.08 7.83 0.006 0.04 10.37 0.002 0.07 8.04 0.005 0.05 0.04 0.84 <0.01 
                   
Sex 1.90 0.17 0.01 18.55 <0.001 0.09 1.62 0.21 0.01 7.49 0.007 0.05 <0.01 0.97 <0.01 1.61 0.21 0.01 
                   
Age 3.47 0.06 0.02 <0.01 0.98 <0.001 0.26 0.61 <0.01 0.11 0.74 <0.01 0.15 0.67 <0.01 3.62 0.06 0.01 
                   
Group  
assignment 1.51 0.21 0.02 5.91 0.001 0.09 5.48 0.001 0.08 13.83 <0.001 0.22 10.57 <0.001 0.18 80.38 <0.001 0.45 
                   
Baseline  
assessment  
of outcome  
variable 






























  6-month VO2peak  
(n=196) 



















Stage 2 1.207 1.373 0.381 
 
-0.059 0.594 0.921 
 
-20.133 22.833 0.379 
Stage 3 -1.542 2.408 0.523 
 
-3.882 1.038 0.000 
 
-99.621 39.725 0.013 
BMI percentile -0.385 0.406 0.344 
 
-0.791 0.198 0.000 
 
-20.181 7.213 0.006 






Aerobic 3.561 1.766 0.045 
 
2.776 0.793 0.001 
 
96.967 30.408 0.002 
Resistance 1.897 1.779 0.288 
 
0.385 0.798 0.630 
 
73.613 30.595 0.017 
Combined 2.746 1.752 0.119 
 
2.261 0.804 0.005 
 
115.253 30.894 0.000 






Male 2.054 1.491 0.170 
 
3.072 0.713 0.000 
 
32.465 25.550 0.205 
            
Age 0.863 0.464 0.064 
 
0.006 0.205 0.975 
 
-4.010 7.859 0.611             
Baseline assessment 
of outcome variable 
0.651 0.052 0.000 
 
0.646 0.065 0.000 
 
0.471 0.064 0.000 
 
Table 4: Parameter estimates for total sample 
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6-month Seated bench 
press weight in kg 
(n=156) 
  6-month Leg Press weight 
in kg 
(n=154) 



















Stage 2 -0.433 1.498 0.773 
 
9.208 7.696 0.233 
 
0.010 0.026 0.694 
Stage 3 -2.178 2.546 0.394 
 
15.606 13.515 0.250 
 
0.002 0.043 0.963 
BMI percentile 1.432 0.445 0.002 
 
6.387 2.252 0.005 
 
-0.001 0.007 0.836 






Aerobic 0.313 2.032 0.878 
 
22.162 10.373 0.034 
 
0.457 0.034 0.000 
Resistance 9.456 1.992 0.000 
 
53.514 10.262 0.000 
 
0.420 0.034 0.000 
Combined 9.343 1.973 0.000 
 
43.185 10.387 0.000 
 
0.428 0.035 0.000 






Male 5.009 1.830 0.007 
 
-0.301 8.948 0.973 
 
0.036 0.029 0.205 
            
Age -0.172 0.525 0.743 
 
-1.073 2.737 0.696 
 
-0.017 0.009 0.058             
Baseline assessment 
of outcome variable 
0.870 0.071 0.000 
 
1.050 0.110 0.000 
    
 




































 Sig. Sig. Sig. Sig. Sig. Sig. 
EOSS-p 0.955 0.564 0.825 0.747 0.924 0.262 
BMI percentile 0.115 0.411 0.305 0.085 0.021 0.504 
Age 0.894 0.326 0.149 0.908 0.766 0.495 
Sex 0.334 0.328 0.043 0.333 0.400 0.336 
Outcome variable assessed at 
baseline 
0.000 0.000 0.000 0.000 0.004 
 
 
Table 6: Associations table for control group only 
 








   6-month PedsQL 
(n=54) 
  6-month VO2peak 
(n=51)  
  6-month treadmill time 
(n=51) 
 













           





Stage 2  0.618 2.812 0.827 
 
0.029 0.994 0.977 
 
-20.714 35.201 0.559 
Stage 3  -0.908 6.911 0.896 
 
-3.675 3.470 0.295 
 
-36.684 123.637 0.768  
 
           
BMI percentile  -1.455 0.905 0.115 
 
-0.298 0.360 0.411 
 
13.689 13.199 0.305  
 
           
Age  0.138 1.033 0.894 
 
-0.390 0.393 0.326 
 
-20.693 14.105 0.149  
 
           





Male  3.083 3.158 0.334 
 
1.289 1.302 0.328 
 
-95.111 45.621 0.043  
 
           
Outcome variable assessed at 
baseline 
 0.726 0.099 0.000 
 
0.730 0.112 0.000 
 
0.610 0.095 0.000 
 
Table 7: Parameter estimates for control group only 
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  6-month Seated bench 
press weight in kg 
(n=41) 
  6-month Leg Press weight 
in kg 
(n=41) 














            





Stage 2 -0.482 2.367 0.840 
 
4.883 12.371 0.696 
 
-0.026 0.016 0.108 
Stage 3 5.083 7.426 0.498 
 
1.050 40.162 0.979 
 
-0.026 0.035 0.459             
BMI percentile 1.502 0.847 0.085 
 
11.078 4.573 0.021 
 
0.003 0.005 0.504             
Age -0.117 0.999 0.908 
 
-1.591 5.304 0.766 
 






Male 3.022 3.079 0.333 
 
-13.352 15.660 0.400 
 
0.018 0.019 0.336             
Outcome variable 
assessed at baseline 
0.861 0.137 0.000 
 
0.629 0.200 0.004 
    
 













treadmill time  
(n=145) 
6-month Seated 
bench press (kg) 
(n=115) 
6-month Leg 






Sig. Sig. Sig. Sig. Sig. Sig. 
EOSS-p 0.284 0.001 0.048 0.657 0.374 0.824 
BMI percentile 0.923 0.000 0.002 0.011 0.073 0.745 
Age 0.029 0.703 0.960 0.744 0.751 0.086 
Sex 0.314 0.000 0.042 0.015 0.585 0.249 
Group 
assignment 





0.000 0.000 0.000 0.000 0.000 
 
 
Table 9: Associations table for exercise groups only 








  6-month VO2peak  
(n=145) 



















Stage 2 1.643 1.591 0.304 
 
0.044 0.734 0.952 
 
-15.288 28.092 0.587 
Stage 3 -1.888 2.617 0.472 
 
-4.021 1.142 0.001 
 





















































Male 1.726 1.708 0.314 
 
3.567 0.857 0.000 
 
62.118 30.297 0.042 
 






Aerobic 0.721 1.776 0.686 
 
0.446 0.860 0.605 
 
-21.622 32.909 0.512 
Resistance -1.039 1.776 0.559 
 
-1.960 0.843 0.022 
 
-45.540 32.342 0.161 
 


























Table 10: Parameter estimates for exercise groups only 
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6-month Seated bench press 
weight in kg 
(n=115) 
  6-month Leg Press weight 
in kg 
(n=113) 











B Std. Error Sig. 





Stage 2 -0.362 1.905 0.850 
 
8.983 9.429 0.343 
 
0.021 0.034 0.536 
Stage 3 -2.636 2.890 0.364 
 
18.845 14.662 0.202 
 
0.007 0.053 0.892 
BMI percentile 1.400 0.539 0.011 
 
4.730 2.612 0.073 
 
-0.003 0.009 0.745 
Age -0.211 0.645 0.744 
 
-1.026 3.222 0.751 
 






Male 5.660 2.293 0.015 
 
5.860 10.695 0.585 
 






Aerobic -9.069 2.223 0.000 
 
-16.961 11.367 0.139 
 
0.027 0.040 0.493 
Resistance 0.078 2.139 0.971 
 
12.092 10.861 0.268 
 
-0.008 0.039 0.840             
Outcome variable 
assessed at baseline 
0.864 0.085 0.000 
 
1.192 0.129 0.000 
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Table 12: Summary of associations 









QOL ✓ (-) X 
Cardiorespiratory 
fitness X ✓ (-) 
Upper body strength X ✓ (+) 
Lower body 
strength X ✓ (+) 
6-months 
QOL X X 
Cardiorespiratory 
fitness ✓ (-) ✓ (-) 
Upper body strength X ✓ (+) 
Lower body 
strength X ✓ (+) 
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Seated bench press 
(kg) 
 
Leg Press (kg) 
 (n=296)   (n=299)   (n=248)   (n=248) 
 F Sig. Eta2  F Sig. Eta2  F Sig. Eta2  F Sig. Eta2 
Corrected  
Model 
16.06 <0.001 0.22 
 
19.35 <0.001 0.25 
 
22.17 <0.001 0.31 
 
13.13 <0.001 0.21 
                
EOSS-p 34.21 <0.001 0.19 
 
1.14 0.32 0.01 
 
0.34 0.71 <0.01 
 
0.06 0.94 <0.01 
                
BMI  
percentile 
0.05 0.82 <0.01 
 
49.71 <0.001 0.15 
 
4.80 0.029 0.02 
 
9.16 0.003 0.04 
                
Sex 7.07 0.008 0.02 
 
76.54 <0.001 0.21 
 
71.90 <0.001 0.23 
 
28.11 <0.001 0.10 
                
Age 2.92 0.09 0.01 
 
3.12 0.08 0.01 
 
6.57 0.011 0.03 
 
11.82 0.001 0.05 
 
Table 13 was created to provide additional baseline data that could not be included in the manuscript. 
